EN DE
Watch Pharma-Bio Serv Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Pharma-Bio Serv Inc (PBSV) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Pharma-Bio Serv Inc stock $0.15, price $0.40, that is 62.5% below the price, quality 65 out of 100. Rating: strongly overvalued. Calculated from audited financials with 2 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

PB Pharma-Bio Serv Inc logo Thin data Nov 4, 2026

Pharma-Bio Serv Inc

PBSV · US
Solid, but very expensive

Our calculation puts a fair price 63% below what the stock costs today.

Quality 65/100
Low debt
Last quarter vs. a year ago: revenue +19%, profit +150%.
Thin margins · 2.7% net margin (TTM)
Mixed vs. peers (5/12)
Fair value $0.1500 · Strongly overvalued
Weak Growth (revenue 5y −16.0 %/yr in USD)
Negative free cash flow
Narrow moat 16/100 · thin data
Thin data
⚠ Thinly traded
Watch Pharma-Bio Serv Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$1.26 $0.3015 Fair Value $0.1500 Oct 2018 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.

How to read this chart

60‑month range $0.3015 – $1.26 · fair‑value band $0.1400 – $0.1700 · the $0.4000 price screens above the $0.1500 fair value. As of Nov 4, 2026.

Follow Pharma-Bio Serv in your weekly email

Every Wednesday you see whether Pharma-Bio Serv is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Pharma-Bio Serv, Inc. operates as a regulatory affair, compliance, and technology transfer services consulting firm in Puerto Rico, the United States, Europe, Brazil, and internationally.

Show moreShow less

The company offers a broad range of technical compliance consulting services, including regulatory affairs, quality assurance, compliance, technology transfer, validation, engineering, project management, and process support.

It serves pharmaceutical, chemical manufacturing, biotechnology, medical device, cosmetic, food industries, and allied products companies. The company was founded in 1993 and is headquartered in Dorado, Puerto Rico.

Stock analysis

Pharma-Bio Serv Inc (PBSV) currently trades at $0.4000, while our model-based Fair Value estimate is $0.1500, 63% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 2 models at a data quality of 95/100, which puts the data coverage at low.

Scenario range: $0.1400 (bear) to $0.1700 (bull), the price of $0.4000 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 65/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Pharma-Bio Serv Inc reported revenue of $9.0M in FY2025 versus $20.1M in FY2021, a compound −18.2%/yr. Reported net income was −$100K in FY2025.

Key figures

Market cap $9.2M Micro · P/E ratio 40.0 · P/S ratio 0.97 · EPS (TTM) $0.0100 · Dividend yield 14.4% · Net margin 2.7% · Return on equity 2.3% · Return on assets (EBIT) −3.5% (5-year average).

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 16 out of 100 (low confidence).

What moves the price

The share trades about 31% below its 52-week high and 14% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 3% fair-value upside, at −63%, PBSV screens richer than that median.

Fair Value models

Bear $0.1400 Fair Value $0.1500 Bull $0.1700
Price $0.4000 · Downside -62.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 12 months old). Earnings retained since then ($0.0100 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Owner Earnings $0.1400 $0.1500 $0.1700 78
NCAV (Graham) $0.3400 $0.5100 $0.6400 55
All 2 models by family
DCF Models
Owner Earnings $0.1400 $0.1500 $0.1700 78
Asset-Based
NCAV (Graham) $0.3400 $0.5100 $0.6400 55

Open the full fair value analysis →

Quality Score breakdown

Overall quality 65/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 24
How much profit the company makes from its sales and capital
Quality Growth 76
Are margins and returns getting better?
Cashflow 39
Do the profits arrive as real cash?
Financial strength 94
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 41
How calm the share price moves, does not count
Price momentum 17
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 16
Distance to the 52-week high, does not count
New shares 83
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

Plus one other filing such as a grant, option exercise or tax withholding. It is not a market purchase or sale.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 14/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−5.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−22.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−16.0%
Start year 2020 (pandemic). Over 10 years: −9.1% a year
Revenue growth 18 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−3.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
10.3% (2020) → −7.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

PBSV screens overvalued: fair value 63% below the price. Compare with Veeva Systems Inc →

Compare Pharma-Bio Serv Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 117 stocks

Beats the industry median on 5/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 65 · Above median
Fair Value upside −62.5% · Below median
Profitability
Return on equity (12 months) 2.3% · Below median
Return on assets −0.7% · Below median
Net margin (12 months) 2.7% · Below median
Operating margin (12 months) −3.1% · Below median
Growth and dividend
Revenue growth (quarter YoY) 19.0% · Above median
Dividend yield (12 months) 14.4% · Top 25%
Balance sheet
Debt / equity 0.05× · Above median

Valuation Multiplesvs Health Information Services median · lower = cheaper

P/E (12 months) 40.0× · Pricier than median
P/B 0.77× · Cheapest 25%
P/S (12 months) 0.97× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 5
FUTURE (revenue growth)95 · sector 46
PAST (return on equity)9 · sector 10
HEALTH (low debt)97 · sector 98
DIVIDEND (yield)100 · sector 41

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Health Information Services stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Veeva Systems Inc VEEV $303.73 $334.10 +10% vs PBSV
HealthEquity, Inc HQY $103.63 $113.99 +10% vs PBSV
Doximity, Inc DOCS $32.51 $35.76 +10% vs PBSV
Inventurus Knowledge Solutions Limited IKS ₹1,657 ₹1,823 +10% vs PBSV
Waystar Holding WAY $28.35 $29.10 +3% vs PBSV
Hinge Health, Inc HNGE $115.76 $51.25 −56% vs PBSV
Pro Medicus Limited PME A$205.49 A$85.12 −59% vs PBSV
BrightSpring Health Services, Inc BTSG $67.15 $25.72 −62% vs PBSV
XtalPi Holdings 2228 HK$6.13 HK$1.53 −75% vs PBSV
Privia Health Group PRVA $24.42 $5.52 −77% vs PBSV

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Pharma-Bio Serv Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Pharma-Bio Serv Inc Fair Value". https://www.fairvalue-calculator.com/stock/PBSV

Frequently asked questions

Is Pharma-Bio Serv Inc (PBSV) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of $0.1500 versus a price of $0.4000, about 63% lower (overvalued).
What is the fair value of PBSV?
Our model-based fair value for Pharma-Bio Serv Inc is $0.1500 (as of Nov 4, 2026), built from audited fundamentals. The current price: $0.4000.
What is the quality score of PBSV?
Pharma-Bio Serv Inc has a Quality Score of 65/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Pharma-Bio Serv Inc (PBSV)?
Our model-based price target is the fair value of $0.1500 (as of Nov 4, 2026) from 2 valuation models. Cautious scenario $0.1400, optimistic scenario $0.1700. It is a calculation from audited fundamentals, not an analyst target.
What is the Pharma-Bio Serv Inc stock forecast for 2026?
Our models put fair value at $0.1500, about 63% lower versus a price of $0.4000 (overvalued). Cautious scenario $0.1400, optimistic scenario $0.1700. The calculation is refreshed regularly with new filings.
What is the revenue of Pharma-Bio Serv Inc (PBSV)?
Pharma-Bio Serv Inc reported trailing-twelve-month revenue of about $9.5M (latest available figure, as of Nov 4, 2026).
Does Pharma-Bio Serv Inc pay a dividend?
Pharma-Bio Serv Inc currently shows a dividend yield of 14.44% relative to its recent price (as of Nov 4, 2026).
How much is the dividend of Pharma-Bio Serv Inc (PBSV)?
Pharma-Bio Serv Inc has a dividend yield of 14.4%.
What is the intrinsic value of Pharma-Bio Serv Inc (PBSV)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Pharma-Bio Serv Inc it is $0.1500 per share (as of Nov 4, 2026), against a price of $0.4000. It is the blended result of 2 valuation models in 2 families (DCF Models, Asset-Based).
Is Pharma-Bio Serv Inc stock overvalued or undervalued in 2026?
As of Nov 4, 2026, PBSV trades above its calculated fair value: price $0.4000, fair value $0.1500, a gap of about −63% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PBSV?
No. The price is what the market pays today ($0.4000); the fair value is what the company's own numbers justify ($0.1500). For Pharma-Bio Serv Inc the two are $0.2500 per share apart. That gap is exactly why we show both numbers side by side.
How much is Pharma-Bio Serv Inc worth?
The market values Pharma-Bio Serv Inc at about $9.2M (market capitalisation, as of Nov 4, 2026). Per share that is $0.4000; our models calculate a fair value of $0.1500 per share.
What do the bullish and bearish scenarios say about PBSV?
Our models span a range for Pharma-Bio Serv Inc: cautious scenario $0.1400, base $0.1500, optimistic $0.1700 per share (as of Nov 4, 2026, price $0.4000). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of PBSV?
Pharma-Bio Serv Inc trades at a price-to-earnings ratio of 40.0 (as of Nov 4, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $0.1500 is built from several models across several years. Median P/E at fiscal year-end, 5 fiscal years (2018 to 2023), reported earnings: 14.9. Other multiples: P/B 0.8, P/S 1.0.
How solid is the balance sheet of Pharma-Bio Serv Inc (PBSV)?
Balance-sheet figures for Pharma-Bio Serv Inc (as of Nov 4, 2026): return on equity 2.3%, debt of 0.05 per unit of equity. They feed the Quality Score of 65/100, which measures business quality independently of the share price.
How far is PBSV from its 52-week high?
Pharma-Bio Serv Inc trades at $0.4000, about 31% below its 52-week high of $0.5800 and 14% above the low of $0.3500 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $0.1500 is for.
Which stocks are comparable to Pharma-Bio Serv Inc?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, Hinge Health, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Pharma-Bio Serv Inc stock attractive at the current price?
The data as of Nov 4, 2026: price $0.4000, calculated fair value $0.1500 (−63%), Quality Score 65/100, from 2 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of PBSV calculated?
We run Pharma-Bio Serv Inc through 2 models from 2 families: DCF Models, Asset-Based. Every model gets the same audited fundamentals; the fair value of $0.1500 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Pharma-Bio Serv Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Pharma-Bio Serv Inc (PBSV)?
The closing price on Nov 6, 2026 was $0.4000. Our model-based fair value is $0.1500, about 63% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Pharma-Bio Serv Inc right now?
The price sits above even our optimistic bull case ($0.1700). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (65/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of Pharma-Bio Serv Inc

How large is the market capitalisation of Pharma-Bio Serv Inc (PBSV)?
The market capitalisation of Pharma-Bio Serv Inc is $9.2M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Pharma-Bio Serv Inc (PBSV)?
The price-to-sales ratio of Pharma-Bio Serv Inc is 0.97 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Pharma-Bio Serv Inc (PBSV)?
Earnings per share at Pharma-Bio Serv Inc are $0.0100 (price ÷ EPS = P/E 40.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Pharma-Bio Serv Inc (PBSV)?
The dividend yield of Pharma-Bio Serv Inc is 14.4%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Pharma-Bio Serv Inc (PBSV)?
The net margin of Pharma-Bio Serv Inc is 2.7% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Pharma-Bio Serv Inc (PBSV)?
The return on equity (ROE) of Pharma-Bio Serv Inc is 2.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Pharma-Bio Serv Inc (PBSV)?
On an EBIT basis the return on assets of Pharma-Bio Serv Inc is −3.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Pharma-Bio Serv Inc (PBSV)?
The operating margin of Pharma-Bio Serv Inc is −3.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Pharma-Bio Serv Inc (PBSV)?
Revenue at Pharma-Bio Serv Inc is growing +19.0% versus a year earlier (3y avg −22.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Pharma-Bio Serv Inc (PBSV)?
Earnings per share at Pharma-Bio Serv Inc are growing +150% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Pharma-Bio Serv Inc (PBSV) generate?
The free cash flow of Pharma-Bio Serv Inc is −$222K (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch Pharma-Bio Serv Inc in the live analysis

One click puts Pharma-Bio Serv Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.